Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer statistics, 2022. CA: Cancer J Clin. 2022;72(1):7–33.
McCormack VA, Boffetta P. Today’s lifestyles, tomorrow’s cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol. 2011;22(11):2349–57.
Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(3):387.
Joko-Fru WY, Jedy-Agba E, Korir A, Ogunbiyi O, Dzamalala CP, Chokunonga E, Wabinga H, Manraj S, Finesse A, Somdyala N, et al. The evolving epidemic of breast cancer in sub-Saharan Africa: results from the African Cancer Registry Network. Int J Cancer. 2020;147(8):2131–41.
Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–37.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.
Provenzano E, Ulaner GA, Chin SF. Molecular classification of breast cancer. PET Clin. 2018;13(3):325–38.
Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch. 2014;465(1):1–14.
Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C, Chen Y, Cao L, Xu Q, Du X, et al. Gene expression profiling for diagnosis of triple-negative breast cancer: a multicenter, retrospective cohort study. Front Oncol. 2019;9:354.
Beca F, Santos R, Vieira D, Zeferino L, Dufloth R, Schmitt F. Primary relapse site pattern in women with triple-negative breast cancer. Pathol Res Pract. 2014;210(9):571–5.
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452–78.
Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479–89.
Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–17.
Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 2021;40(2):537–47.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
Kim SK, Ahn SG, Mun JY, Jeong MS, Chu IS. Genomic signature of the standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography in breast cancer. Cancers. 2020;12(2):497.
Colin C, Madden SF, Padraig D, Aherne ST, Helena J, Lorraine OD, Gallagher WM, Hennessy BT, Michael M, John C. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis. 2013;10:2300–8.
Rla B, Algc D, Bk A. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease – ScienceDirect. Pharmacol Ther. 2007;115(2):177–207.
Brzozowska M, Caka J: Review: Occurrence and distribution of galanin in the physiological and inflammatory states in the mammalian gastrointestinal tract. Front Immunol. 2020;11:602070.
Koller A, Bianchini R, Schlager S, Münz C, Kofler B, Wiesmayr S. The neuropeptide galanin modulates natural killer cell function. Neuropeptides. 2017;64:109–15.
Zhang L, Fang P, Chai C, Shao L, Mao H, Qiao D, Kong G, Dong X, Shi M, Zhang Z, et al. Galanin expression is down-regulated in patients with gastric cancer. J Int Med Res. 2019;47(3):1241–9.
Nagayoshi K, Ueki T, Tashiro K, Mizuuchi Y, Manabe T, Araki H, Oda Y, Kuhara S, Tanaka M. Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer. Oncol Rep. 2015;33(2):539–46.
Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res. 2012;18(19):5412–26.
Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, Ueda Y, Tono T, Carey TE. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene. 2007;26(39):5762–71.
Perel Y, Amrein L, Dobremez E, Rivel J, Daniel JY, Landry M. Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status. Br J Cancer. 2002;86(1):117–22.
van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–32.
Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K: CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci 2020;21(18):6968.
Telli ML, Nagata H, Wapnir I, Acharya CR, Zablotsky K, Fox BA, Bifulco CB, Jensen SM, Ballesteros-Merino C, Le MH, et al. Intratumoral plasmid IL12 expands CD8(+) T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy. Clin Cancer Res. 2021;27(9):2481–93.
Schmidt M, Bohm D, Von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Can Res. 2008;68(13):5405–13.
Vagia E, Mahalingam D, Cristofanilli M: The landscape of targeted therapies in TNBC. Cancers (Basel) 2020;12(4).
Song L, Guo X, Zhao F, Wang W, Zhao Z, Jin L, Wu C, Yao J, Ma Z. TTC36 inactivation induce malignant properties via Wnt-β-catenin pathway in gastric carcinoma. J Cancer. 2021;12(9):2598–609.
Chai H, Xia L, Zhang L, Yang J, Zhang Z, Qian X, Yang Y, Pan W. An adaptive transfer-learning-based deep Cox neural network for hepatocellular carcinoma prognosis prediction. Front Oncol. 2021;11: 692774.
Liu Q, Gao J, Chen X, Chen Y, Chen J, Wang S, Liu J, Liu X, Li J. HBP21: a novel member of TPR motif family, as a potential chaperone of heat shock protein 70 in proliferative vitreoretinopathy (PVR) and breast cancer. Mol Biotechnol. 2008;40(3):231–40.
He M, Hu C, Deng J, Ji H, Tian W. Identification of a novel glycolysis-related signature to predict the prognosis of patients with breast cancer. World J Surg Oncol. 2021;19(1):294.
Zhou X, Xiao C, Han T, Qiu S, Wang M, Chu J, Sun W, Li L, Lin L. Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis. World J Surg Oncol. 2020;18(1):254.
Jia R, Weng Y, Li Z, Liang W, Ji Y, Liang Y, Ning P. Bioinformatics analysis identifies IL6ST as a potential tumor suppressor gene for triple-negative breast cancer. Reprod Sci. 2021;28(8):2331–41.
Wei LM, Li XY, Wang ZM, Wang YK, Yao G, Fan JH, Wang XS. Identification of hub genes in triple-negative breast cancer by integrated bioinformatics analysis. Gland Surg. 2021;10(2):799–806.
Xiao X, Zhang Z, Luo R, Peng R, Sun Y, Wang J, Chen X. Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses. Oncol Lett. 2021;21(5):363.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.